Showing 6601-6610 of 9119 results for "".
- FDA Seeks More Information on Pliaglishttps://practicaldermatology.com/news/20120419-fda_seeks_more_information_on_pliaglis/2459818/FDA's Complete Response Letter to Galderma Laboratories LP outlines additional information the FDA requires before it will approve the sNDA for Pliaglis, developer Nuvo Research, Inc. reports. The response is to the supplemental New Drug App
- Amgen, Pfizer Will No Longer Co-Market Enbrelhttps://practicaldermatology.com/news/20120419-amgen_pfizer_will_no_longer_co-market_enbrel/2459819/Amgen and Pfizer will end co-promotion of Enbrel (etanercept) in North America this summer, the companies tell the Wall Street Journal. Amgen will assume full marketing responsibilities in the US, effective July 23.
- Slight Uptick for Biologics Predicted in EUhttps://practicaldermatology.com/news/20120419-slight_uptick_for_biologics_predicted_in_eu/2459820/In a recent TreatmentTrends© study with EU5 dermatologists, BioTrends Research Group, LLC finds that there has been a slight increase in the use of biologics in all of the EU5 countries except Italy, where usage has remained constant. Future prescribing habits will see moderate increases in prescrib
- Efficacy Data for LaViv Now Publishedhttps://practicaldermatology.com/news/20120418-efficacy_data_for_laviv_now_published/2459822/Data demonstrating that LaViv (azficel-T, Fibrocell Science, Inc.) is effective for the aesthetic improvement of moderate to severe smile lines are now published online in Dermatologic Surgery. The combined results of two identically-designed, Phase III, multi-
- Vichy Partners With timeRAZOR for Free iPhone, Android Apphttps://practicaldermatology.com/news/20120404-vichy_partners_with_timerazor_for_free_iphone_android_app/2459828/With the new timeRAZOR app, Vichy and timeRAZOR help keep users in the know on events occurring close to where they work, live, or plan to be. timeRAZOR pairs technologic components like geolocation with its own Massive Event Selection Engine, i
- Prostaglandin D2 A Potential New Target for Alopecia Therapyhttps://practicaldermatology.com/news/20120326-prostaglandin_d2_a_potential_new_target_for_alopecia_therapy/2459832/Prostaglandin D2 (PGD2) appears to inhibit hair growth in androgenetic alopecia (AGA) and may be potential target for its treatment, new research suggests (Sci Transl Med. 4(126):126ra34). Researchers show that PG
- La Roche-Posay Launches Mobile “Dermatologist By Your Side” Educationhttps://practicaldermatology.com/news/20120320-la_roche-posay_launches_mobile_dermatologist_by_your_side_education/2459835/When patients want advice on skin care products in the pharmacy or anywhere, they can dial **DERM from a mobile phone. An automated text response leads them to a dedicated YouTube.com site, featuring educational videos from dermatologists Kavita Mariwala, MD and Shirley Chi, MD. The program from
- Skinvisible Granted Patent for UVA Absorberhttps://practicaldermatology.com/news/20120320-skinvisible_granted_patent_for_uva_absorber/2459836/Skinvisible Pharmaceuticals, Inc. has been granted a new patent for its UVA sunscreen absorber. Skinvisible's new formulation with avobenzone provides eight hours of photostability, an advantage for those who spend many hours in the sun. The ingredi
- Galderma Completes Phase 3 Rosacea Erythema Studyhttps://practicaldermatology.com/news/20120320-galderma_completes_of_phase_3_rosacea_erythema_study/2459839/Galderma Laboratories announced the completion of two independent Phase 3 clinical trials that evaluated the safety and efficacy of CD07805/47, a proprietary topical gel under investigation in patients with moderate to severe facial erythema of
- Kythera Initiates Phase 3 trials for Investigational Injectablehttps://practicaldermatology.com/news/20120320-kythera_initiates_phase_3_trials_for_investigational_injectable/2459841/Kythera Biopharmaceuticals has initiated two Phase 3 trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental fat. The Phase 3 trials, known as REFINE-1 and REFINE-2 (Randomized Doubl